

EXECUTIVE SUMMARY

Full Year 2024




Main figures €Mn

Op. Revenue 763.7 (-8%)	EBITDA 207.4 (-15%)	EBIT 179.4 (-19%)
Net profit 136.9 (-20%)	Capex 62.2 (+13%)	Net debt 85.1


2025 operating revenue guidance:
Decrease by a mid-single-digit percentage vs 2024

- ✓ ROVI announces an agreement to support the manufacture of pre-filled syringes.
- ✓ ROVI executes the share capital reduction approved by the 2024 Ordinary General Meeting.
- ✓ ROVI improves its ESG risk rating for the fifth year running in the Sustainalytics ESG risk ranking.

Operating revenue €Mn



Specialty pharma business €Mn



Heparin franchise*

33% of operating revenue

€248.7m -1%

Enoxaparin sales €145.2m -2%

- ✓ Q4 2024 was the strongest quarter of the year in terms of sales, due to a higher concentration of orders from partners.
- ✓ Launched in 41 countries.

Bemiparin sales €96.4m +2%

- ✓ Full year sales of Bemiparin increased mainly by higher international sales linked to higher orders from partners in China, Greece and Turkey.

Other prescription-based pharmaceutical products

Neparvis® €51.4m +13%

Okedi® €28.8m +101%

- ✓ Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Marketed in Europe, and approved in Australia, Taiwan & Canada.

* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins


CDMO⁽¹⁾ business €Mn




⁽¹⁾Contract Development and Manufacturing Organisation

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 38-42) of the press release on the financial results for the full year 2024. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>


Gross profit €Mn



SG&A expenses €Mn



EBITDA €Mn



R&D expenses €Mn €25.8

+3%


Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	Schizophrenia	Approved	Marketed in Europe, and approved in Australia, Taiwan & Canada
Letrozole ISM®, annual	Breast Cancer	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole LEBE, quarterly	Breast Cancer	Phase I	
Risperidone, quarterly	Schizophrenia	Phase I	

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRS, please consult the information included on this subject on page 1 and Appendix 2 (pages 38-42) of the press release on the financial results for the full year 2024. Said document is available on ROVI's website and may be accessed on the following link <https://www.rovi.es/en/shareholders-investors/financial-business-information>

Net profit €Mn



Net profit Pre-R&D⁽¹⁾ €Mn

€156.7m

-17%

(1) Calculated excluding R&D expenses in FY 2024 and FY 2023

News flow

SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ Additional new products to be launched
- ✓ Granting by the competent local authorities of the marketing authorisation of an Enoxaparin biosimilar outside Europe

CDMO

- ✓ Evolution of Moderna's vaccine manufacturing
- ✓ Announcement of new contracts
- ✓ Enlarge the production capacities in our plants

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe, Canada, Australia and other countries
- ✓ Phase I clinical development of a three-monthly formulation of letrozole (Letrozole LEBE)
- ✓ Phase I clinical development of Risperidone for a 3-monthly injection